A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccines, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Poland. Open to participants aged 41 Days to 99 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-15.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate (13vPnC) vaccine compared to pilot scale 13vPnC in healthy infants when given with routine pediatric vaccines.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent Pneumococcal Conjugate Vaccine
Biological: 13-valent Pneumococcal Conjugate Vaccine
1 dose at 2,3,4 and 12 months of age
Percentage of Participants Achieving Antibody Level ≥0.35μg/mL in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after 3-dose infant series (5 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events (Infant Series)
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events (Toddler Series)
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.
Time frame: During the 4-day period after toddler dose
Geometric Mean Antibody Concentration in 13vPnC Manufacturing Scale Group Relative to 13vPnC Pilot Scale Group After the 3-Dose Infant Series
Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: One month after 3-dose infant series (5 months of age)
Participants were recruited in Poland from June 2007 to August 2007.
| Milestone | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Started | 135 | 134 |
| Vaccinated dose 1 | 134 | 134 |
| Vaccinated dose 2 | 132 | 133 |
| Vaccinated dose 3 | 132 | 133 |
| Completed | 131 | 133 |
| Not completed | 4 | 1 |
| Withdrew: Withdrawal by parent/guardian request | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Milestone | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Started | 131 | 133 |
| Completed | 131 | 131 |
| Not completed | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Started | 131 | 131 |
| Completed | 131 | 130 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Percentages of participants achieving WHO predefined antibody threshold ≥0.35μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Common Serotypes-Serotype 4 | 97.7 (93.3 to 99.5) | 96.9 (92.4 to 99.2) |
| Common Serotypes-Serotype 6B | 77.3 (69.1 to 84.3) | 74.0 (65.7 to 81.3) |
| Common Serotypes-Serotype 9V | 98.4 (94.5 to 99.8) | 96.2 (91.3 to 98.7) |
| Common Serotypes-Serotype 14 | 92.9 (87.0 to 96.7) | 94.5 (89.1 to 97.8) |
| Common Serotypes-Serotype 18C | 96.1 (91.1 to 98.7) | 93.1 (87.4 to 96.8) |
| Common Serotypes-Serotype 19F | 98.4 (94.4 to 99.8) | 97.7 (93.5 to 99.5) |
| Common Serotypes-Serotype 23F | 82.8 (75.1 to 88.9) | 81.7 (74.0 to 87.9) |
| Additional Serotypes-Serotype 1 | 93.0 (87.1 to 96.7) | 90.8 (84.5 to 95.2) |
| Additional Serotypes-Serotype 3 | 93.7 (88.0 to 97.2) | 95.4 (90.3 to 98.3) |
| Additional Serotypes-Serotype 5 | 90.6 (84.2 to 95.1) | 88.5 (81.8 to 93.4) |
| Additional Serotypes-Serotype 6A | 85.2 (77.8 to 90.8) | 86.3 (79.2 to 91.6) |
| Additional Serotypes-Serotype 7F | 100.0 (97.2 to 100.0) | 100.0 (97.2 to 100.0) |
| Additional Serotypes-Serotype 19A | 99.2 (95.7 to 100.0) | 99.2 (95.8 to 100.0) |
Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant(Sig) (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (Mod) (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Manufacturing Dose 1 | 13vPnC Pilot Dose 1 | 13vPnC Manufacturing Dose 2 | 13vPnC Pilot Dose 2 | 13vPnC Manufacturing Dose 3 | 13vPnC Pilot Dose 3 | 13vPnC Manufacturing Toddler Dose | 13vPnC Pilot Toddler Dose |
|---|---|---|---|---|---|---|---|---|
| Tenderness-Any (n=133,130,128,128,124,119,115,117) | 18.8 | 20.0 | 20.3 | 17.2 | 15.3 | 12.6 | 24.3 | 29.1 |
| Tenderness-Sig (n=131,129,128,128,124,119,112,114) | 0.8 | 3.9 | 1.6 | 3.1 | 1.6 | 0.0 | 1.8 | 3.5 |
| Swelling-Any (n=132,130,129,129,126,122,113,115) | 25.0 | 20.0 | 30.2 | 27.1 | 29.4 | 30.3 | 22.1 | 26.1 |
| Swelling-Mild (n=132,130,129,129,126,121,113,115) | 22.7 | 17.7 | 29.5 | 25.6 | 27.0 | 25.6 | 22.1 | 25.2 |
| Swelling-Mod (n=132,129,128,128,124,120,113,114) | 6.1 | 7.0 | 8.6 | 8.6 | 8.9 | 13.3 | 8.8 | 8.8 |
| Swelling-Severe(n=131,129,128,128,124,119,112,113) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Redness-Any (n=132,131,129,131,125,123,115,116) | 28.8 | 24.4 | 37.2 | 33.6 | 40.0 | 34.1 | 37.4 | 42.2 |
| Redness-Mild (n=132,131,129,131,125,123,115,115) | 28.8 | 22.9 | 36.4 | 33.6 | 38.4 | 33.3 | 33.9 | 36.5 |
| Redness-Mod (n=131,129,128,128,124,119,113,114) | 0.0 | 1.6 | 3.1 | 1.6 | 5.6 | 3.4 | 10.6 | 12.3 |
| Redness-Severe(n=131,129,128,128,124,119,112,113) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 |
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, use of medication (Meds)to prevent symptoms (sx), and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Manufacturing Dose 1 | 13vPnC Pilot Dose 1 | 13vPnC Manufacturing Dose 2 | 13vPnC Pilot Dose 2 | 13vPnC Manufacturing Dose 3 | 13vPnC Pilot Dose 3 |
|---|---|---|---|---|---|---|
| Fever ≥38°C but ≤39°C (n=132,130,129,130,124,121) | 18.2 | 19.2 | 16.3 | 20.0 | 11.3 | 17.4 |
| Fever >39°C but ≤40°C (n=131,129,128,128,124,119) | 0.8 | 0.8 | 0.8 | 1.6 | 0.0 | 3.4 |
| Fever >40°C (n=131,129,128,128,124,119) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Decreased appetite (n=133,129,129,128,125,121) | 20.3 | 24.0 | 14.7 | 15.6 | 16.8 | 19.0 |
| Irritability (n=134,131,130,131,127,123) | 50.0 | 51.9 | 53.8 | 49.6 | 41.7 | 37.4 |
| Increased sleep (n=132,129,128,129124,121) | 41.7 | 39.5 | 25.0 | 29.5 | 20.2 | 30.6 |
| Decreased sleep (n=132,130,129,129,124,123) | 27.3 | 32.3 | 24.0 | 20.9 | 18.5 | 19.5 |
| Meds to treat sx (n=132,130,128,128,124,123) | 12.9 | 17.7 | 13.3 | 14.1 | 8.9 | 14.6 |
| Meds to prevent sx (n=132,130,128,129124,121) | 12.9 | 9.2 | 11.7 | 10.1 | 10.5 | 8.3 |
Systemic events (fever ≥ 38 degrees Celsius \[C\] but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C), decreased appetite, irritability, increased sleep, decreased sleep, use of medication to prevent symptoms, and use of medication to treat symptoms) were collected using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Fever ≥38°C but ≤39°C (n=114,114) | 14.0 | 13.2 |
| Fever >39°C but ≤40°C (n=112,113) | 0.9 | 0.9 |
| Fever >40°C (n=112,113) | 0.0 | 0.0 |
| Decreased appetite (n=115,117) | 20.9 | 23.1 |
| Irritability (n=119,123) | 40.3 | 44.7 |
| Increased sleep (n=114,119) | 18.4 | 16.8 |
| Decreased sleep (n=116,117) | 13.8 | 13.7 |
| Medication to treat symptoms (n=113,115) | 17.7 | 17.4 |
| Medication to prevent symptoms (n=114,114) | 12.3 | 12.3 |
Antibody concentration/geometric mean concentration (GMC) as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC Manufacturing | 13vPnC Pilot |
|---|---|---|
| Common Serotypes-Serotype 4 | 2.09 (1.81 to 2.40) | 1.55 (1.34 to 1.79) |
| Common Serotypes - Serotype 6B | 0.80 (0.65 to 0.98) | 0.83 (0.66 to 1.06) |
| Common Serotypes - Serotype 9V | 1.28 (1.13 to 1.43) | 1.21 (1.08 to 1.37) |
| Common Serotypes - Serotype 14 | 2.15 (1.77 to 2.61) | 2.30 (1.91 to 2.77) |
| Common Serotypes - Serotype 18C | 1.60 (1.38 to 1.87) | 1.51 (1.31 to 1.75) |
| Common Serotypes - Serotype 19F | 1.60 (1.40 to 1.83) | 1.64 (1.44 to 1.86) |
| Common Serotypes - Serotype 23F | 0.82 (0.69 to 0.98) | 0.92 (0.77 to 1.10) |
| Additional Serotypes - Serotype 1 | 1.42 (1.21 to 1.66) | 1.29 (1.10 to 1.51) |
| Additional Serotypes - Serotype 3 | 1.20 (1.05 to 1.38) | 1.21 (1.06 to 1.37) |
| Additional Serotypes - Serotype 5 | 0.96 (0.84 to 1.09) | 1.00 (0.87 to 1.16) |
| Additional Serotypes - Serotype 6A | 0.87 (0.74 to 1.03) | 1.05 (0.89 to 1.25) |
| Additional Serotypes - Serotype 7F | 2.00 (1.77 to 2.25) | 2.14 (1.89 to 2.42) |
| Additional Serotypes - Serotype 19A | 2.19 (1.91 to 2.50) | 2.31 (2.05 to 2.61) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Manufacturing Infant Series | — | 4/134 (3%) | 70/134 (52.2%) |
| 13vPnC Pilot Infant Series | — | 2/134 (1.5%) | 68/134 (50.7%) |
| 13vPnC Manufacturing Post-Infant Series | — | 10/134 (7.5%) | 3/134 (2.2%) |
| 13vPnC Pilot Post-Infant Series | — | 11/134 (8.2%) | 7/134 (5.2%) |
| 13vPnC Manufacturing Toddler Series | — | 0/131 (0%) | 48/131 (36.6%) |
| 13vPnC Pilot Toddler Series | — | 1/131 (0.8%) | 55/131 (42%) |
| Event | 13vPnC Manufacturing Infant Series | 13vPnC Pilot Infant Series | 13vPnC Manufacturing Post-Infant Series | 13vPnC Pilot Post-Infant Series | 13vPnC Manufacturing Toddler Series | 13vPnC Pilot Toddler Series |
|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/134 | 0/134 | 3/134 | 4/134 | 0/131 | 1/131 |
| PneumoniaInfections and infestations | 1/134 | 0/134 | 2/134 | 3/134 | 0/131 | 0/131 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/134 | 0/134 | 2/134 | 0/134 | 0/131 | 0/131 |
| BronchitisInfections and infestations | 1/134 | 0/134 | 1/134 | 2/134 | 0/131 | 0/131 |
| DiarrhoeaGastrointestinal disorders | 0/134 | 1/134 | 2/134 | 1/134 | 0/131 | 0/131 |
| LaryngitisInfections and infestations | 1/134 | 0/134 | 2/134 | 1/134 | 0/131 | 0/131 |
| Upper respiratory tract infectionInfections and infestations | 0/134 | 1/134 | 1/134 | 2/134 | 0/131 | 0/131 |
| BronchopneumoniaInfections and infestations | 0/134 | 0/134 | 1/134 | 0/134 | 0/131 | 0/131 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/134 | 0/134 | 0/134 | 0/134 | 0/131 | 0/131 |
| ConjunctivitisEye disorders | 0/134 | 0/134 | 0/134 | 1/134 | 0/131 | 0/131 |
| Event | 13vPnC Manufacturing Infant Series | 13vPnC Pilot Infant Series | 13vPnC Manufacturing Post-Infant Series | 13vPnC Pilot Post-Infant Series | 13vPnC Manufacturing Toddler Series | 13vPnC Pilot Toddler Series |
|---|---|---|---|---|---|---|
| IrritabilityGeneral disorders | 70/130 | 65/131 | 0/134 | 0/134 | 0/131 | 0/131 |
| IrritabilityGeneral disorders | 67/134 | 68/131 | 0/134 | 0/134 | 48/119 | 55/123 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 38/132 | 32/131 | 0/134 | 0/134 | 43/115 | 49/116 |
| IrritabilityGeneral disorders | 53/127 | 46/123 | 0/134 | 0/134 | 0/131 | 0/131 |
| Increased sleepGeneral disorders | 55/132 | 51/129 | 0/134 | 0/134 | 21/114 | 20/119 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 50/125 | 42/123 | 0/134 | 0/134 | 0/131 | 0/131 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 48/125 | 41/123 | 0/134 | 0/134 | 0/131 | 0/131 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 48/129 | 44/131 | 0/134 | 0/134 | 0/131 | 0/131 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 38/132 | 30/131 | 0/134 | 0/134 | 39/115 | 42/115 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 47/129 | 44/131 | 0/134 | 0/134 | 0/131 | 0/131 |
| Age Continuous(months) | 13vPnC Manufacturing | 13vPnC Pilot | Total |
|---|---|---|---|
| Mean | 2.1 ± 0.6 | 2.1 ± 0.5 | 2.1 ± 0.5 |
| Sex: Female, Male(Participants) | 13vPnC Manufacturing | 13vPnC Pilot | Total |
|---|---|---|---|
| Female | 65 | 67 | 132 |
| Male | 70 | 67 | 137 |
The record gives a start of Jun 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 11 months after primary completion. A results delay was requested in Feb 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →